These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 23468082

  • 21. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL, Wong CH, Lau CP, Zhou Q, Hui CW, Lui VW, Ma BB, Chan AT, Yeo W.
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [Abstract] [Full Text] [Related]

  • 22. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR.
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [Abstract] [Full Text] [Related]

  • 23. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
    Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.
    Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
    [Abstract] [Full Text] [Related]

  • 24. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA, Loch DC, Pollock PM.
    Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
    [Abstract] [Full Text] [Related]

  • 25. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y, Cho H, Hur W, Sim T.
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [Abstract] [Full Text] [Related]

  • 26. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA.
    Cancer; 2009 Sep 01; 115(17):3887-96. PubMed ID: 19484784
    [Abstract] [Full Text] [Related]

  • 27. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.
    Breast Cancer Res Treat; 2012 Jan 01; 131(2):425-36. PubMed ID: 21394501
    [Abstract] [Full Text] [Related]

  • 28. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS, Cranmer LD.
    BMC Res Notes; 2014 Nov 18; 7():812. PubMed ID: 25406429
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
    Doghman M, Lalli E.
    Mol Cell Endocrinol; 2012 Nov 25; 364(1-2):101-4. PubMed ID: 22960230
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
    Oda K.
    Gan To Kagaku Ryoho; 2011 Jul 25; 38(7):1084-7. PubMed ID: 21772091
    [Abstract] [Full Text] [Related]

  • 33. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
    Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T.
    Mol Cancer Ther; 2011 Jun 25; 10(6):1059-71. PubMed ID: 21482695
    [Abstract] [Full Text] [Related]

  • 34. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L.
    J Clin Oncol; 2010 Oct 20; 28(30):4554-61. PubMed ID: 20855840
    [Abstract] [Full Text] [Related]

  • 35. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 Oct 20; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 36. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
    Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R.
    Lancet Oncol; 2015 Jun 20; 16(6):686-94. PubMed ID: 25981814
    [Abstract] [Full Text] [Related]

  • 37. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
    Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, Cheng J, Li X, Campbell K, Dodion P, Haluska FG.
    J Clin Oncol; 2015 Nov 01; 33(31):3576-82. PubMed ID: 26077241
    [Abstract] [Full Text] [Related]

  • 38. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
    Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA.
    J Natl Cancer Inst; 2016 Dec 01; 108(12):. PubMed ID: 27576731
    [Abstract] [Full Text] [Related]

  • 39. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.
    Clin Cancer Res; 2008 Nov 15; 14(22):7272-83. PubMed ID: 19010843
    [Abstract] [Full Text] [Related]

  • 40. [Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice].
    Wu T, Jiang X, Xu B, Wang Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct 30; 40(10):1448-1456. PubMed ID: 33118510
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.